Third dose of ChAdOx1 nCoV-19 vaccine and prolonged second dose-intervals are both associated with increased antibody titers
1. An interval of 44-45 weeks between the first and second dose resulted in a four-fold increase in median antibody ...
Tag: ChAdOx1
Mixed vaccination with ChAdOx1-S followed by BNT162b2 induces a robust humoral immune response
1. Levels of antibodies against the trimeric spike protein and receptor-binding domain were 36- and 77-fold higher in the BNT162b2 ...
Single dose mass vaccination against COVID-19 is linked with reductions in hospital admissions
1. The initial doses of the Pfizer and AstraZeneca vaccines were 91% and 88% efficacious in reducing COVID-19 hospitalizations one ...
ChAdOx1 nCoV-19 (AstraZeneca) vaccine is effective against the SARS-CoV-2 B.1.1.7 variant
1. The AstraZeneca vaccine was 70.4% effective against the B.1.1.7 lineage, compared to 81.5% effective against non-B.1.1.7 lineages. 2. The ...
ChAdOx1-nCoV-19 vaccine maintains efficacy despite a longer prime-boost interval
1. Overall vaccine efficacy at least 14-days after the second dose was 66.7%. 2. After the initial 21-day exclusion period, ...
